In USA, 795.000 individuals are faced with new or recurrent stroke attacks each year and 87% of all stroke cases are ischemic.1 It is recommended that the time spent for imaging techniques should not delay the treatment, especially in patients who are candidates for intravenous fibrinolytic treatment.6 Regarding this issue, the diagnostic value of new biochemical markers like myelin basic protein, neuron specific enolase and B-type natriuretic peptide has been investigated.7,8. This evidence concerns the gene MBP and stroke disorder.